Pharma Focus Asia
KP - Sustainable Packaging Solutions

Sharp Announces US $11m Investment to Fund New Multiple Phase Pharmaceutical Manufacturing


Sharp Clinical Services (Sharp) has announced US $11 million investment to fund a new multiple-phase pharmaceutical manufacturing, packaging and distribution facility in Wales.


The investment in European Clinical Services Centre of Excellence also includes US $620m from the Welsh Government. In addition, it helps company to satisfy increased demand for Phase III clinical and commercial services.

The initial phase of the 11 million expansions will be completed by late 2018. It involves the acquisition and renovation of an 11, 000 square foot facility within the site. At first, 75, 000 square foot will be fitted out.

The 10-acre site in Rhymney, South Wales also benefits from the potential for further significant capacity expansion. On the other hand, it will replace the company’s existing site in Crickhowell, Powys.

It will also triple Sharp’s clinical service capacity for the global pharmaceutical, biotech and clinical research sectors. Sharp will be able to offer dull service support for larger global clinical studies from this new European clinical centre of excellence by developing its manufacturing and analytical capabilities.

It will also add automated bottling, blistering and serialization as well as IRT Services for clinical trial management. This investment would give a blank canvas to design a modern contract packaging, manufacturing and distribution facility that meets the evolving needs of drug development companies with single or multiple products at any clinical scale.

The Rhymney site will enable us to offer expanded capacity, scalability and automation that can simultaneously support multiple large scale Phase III studies, as well as projects at an earlier trail stage.

Sharp plans to commence the first phase of the expansion project in 2017, with completion expected for late 2018. The project is a welcome boost to the local economy in South Wales and the wider life science sector in the UK.

This investment allows Sharp to double its headcount and nearly 73 new jobs and safeguards a further 70 jobs with Welsh Government Support.


NameSharp Clinical Services (Sharp)
LocationWales, UK
TypeManufacturing, Packaging and Distribution Facility
Estimated Cost$11 Million
Parties InvolvedSharp Clinical Services (Sharp)
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelTFS - ODW - The Technology Debate: Single-Use vs. Stainless SteelAsia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 20244th Middle East Pharmacoeconomics and Drug Policy Summit 2024Digital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference
Searching for an end-to-end patient tech solution?